GLP-1 medications have evolved incredibly fast over the last few years.
First came drugs like Ozempic® and Wegovy®. Then medications like Zepbound® pushed weight loss results even further. But while those drugs were still dominating headlines, researchers were already working on the next generation of metabolic treatments.
One of the most anticipated upcoming medications is CagriSema.
Developed by Novo Nordisk, CagriSema is currently being reviewed as a treatment for obesity and type 2 diabetes. What makes it different is that it doesn’t just build on traditional GLP-1 science. It introduces an entirely new hormone pathway into the equation.
That’s why so many researchers view it as one of the biggest potential shifts in obesity medicine since semaglutide first arrived.
What Is CagriSema?
CagriSema is a once-weekly injectable medication currently being studied for weight management and type 2 diabetes. Unlike medications built around a single active ingredient, CagriSema combines two separate compounds into one injection pen.
Those compounds are:
• Semaglutide, the same GLP-1 ingredient used in Wegovy® and Ozempic®
• Cagrilintide, a newer amylin analogue designed to target appetite and fullness differently than GLP-1 medications alone
The addition of cagrilintide is what makes CagriSema especially interesting.
The Amylin Difference
Most current weight loss medications focus heavily on hormones like GLP-1 or GIP. CagriSema adds another hormone pathway called amylin into the mix.
Amylin is a hormone naturally released alongside insulin by the pancreas. Researchers believe it plays a major role in fullness, satiety, and long-term energy balance.
While semaglutide helps reduce appetite and slow digestion, cagrilintide appears to strengthen feelings of fullness through additional pathways in the brain.
The goal is basically a layered approach to appetite regulation instead of relying on one hormone system alone.
How CagriSema Works
Researchers describe the medication as a kind of “dual-action” approach to metabolic health.
The two compounds work together in several ways:
• Stronger appetite suppression and fullness signals
• Slower digestion and gastric emptying
• Reduced food cravings and “food noise”
• Improved blood sugar regulation
• Better control of post-meal glucose spikes
The Clinical Trial Results Got Attention Quickly
A major reason CagriSema created so much buzz is because the early trial results were extremely strong.
The REDEFINE 1 Obesity Trial
In a large 68-week study involving adults with obesity but without diabetes, patients taking CagriSema achieved an average weight reduction of 22.7%.
Some of the more notable findings included:
• Over half of participants moved below the BMI threshold for clinical obesity
• Nearly 40% of patients lost 25% or more of their body weight
Those numbers immediately put CagriSema into the conversation with the most powerful obesity treatments currently in development.
The REIMAGINE 2 Diabetes Trial
Researchers also studied CagriSema in patients with type 2 diabetes, where weight loss is often harder to achieve because of metabolic resistance.
In those trials, patients still experienced substantial weight reduction alongside strong improvements in blood sugar control.
What Could Make CagriSema Different?
One thing researchers are watching closely is whether multi-hormone therapies can avoid the early weight-loss plateau that sometimes happens with single-hormone medications.
Some trial data suggests patients on CagriSema continued steadily losing weight longer than expected instead of plateauing as quickly.
That could become a major advantage if future studies continue showing the same trend.
The Potential Downsides
Like most medications in this category, CagriSema is not side-effect free.
Because both compounds slow digestion, gastrointestinal side effects are still common during dose escalation.
Patients in clinical trials reported symptoms like:
• Nausea
• Vomiting
• Diarrhea
• Constipation
The medication also still requires weekly injections, which may matter for patients hoping future obesity treatments move entirely toward oral medications.
How Does It Compare to Zepbound?
One of the biggest questions surrounding CagriSema is how it compares to tirzepatide, the active ingredient in Zepbound®.
Early head-to-head data showed extremely competitive results between the two medications, with both producing very high levels of weight loss.
Researchers are also already studying higher-dose versions of CagriSema, which means the medication may continue evolving even after launch.
Why CagriSema Matters
The bigger story behind CagriSema may not just be the amount of weight loss itself.
It represents a broader shift toward multi-hormone metabolic therapy, where medications target several appetite and energy-regulation systems at the same time instead of relying on a single pathway.
That approach could shape the next generation of obesity and diabetes treatment.
And if the current trial data continues holding up through final approval stages, CagriSema may end up becoming one of the most important medications in the next phase of metabolic medicine.
